

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
10278-009001Application No.
09/407,605
**Information Disclosure Statement
by Applicant**
 (Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant
Allan M. Miller et al.Filing Date
September 28, 1999Group Art Unit
1643**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

RECEIVED

OCT 17 2002

TECH CENTER 1600:2900

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
CYK	AG	96/09378 A1	03/28/1996	WIPO				
CYK	AH	98/12207 A1	03/26/1998	WIPO				
	AI							
	AJ							
	AK							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
CYK	AL	Peter Lind et al., "Novel forms of B-domain-deleted recombinant factor VIII molecules Construction and biochemical characterization", <u>European Journal of Biochemistry</u> , Vol. 232, No. 1, pages 19-27 (August 15, 1995)
	AM	Carmel M. Lynch et al, "Sequences in the Coding Region of Clotting Factor VIII Act as Dominant Inhibitors of RNA Accumulation and Protein Production", <u>Human Gene Therapy</u> , Vol. 4, No. 3, pages 259-272 (June 1, 1993)
CYK	AN	Louise C. Wasley et al., "PACE Furin Can Process the Vitamin K-dependent Pro-factor IX Precursor within the Secretory Pathway", <u>Journal of Biological Chemistry</u> , Vol. 268, No. 12, pages 8458-8465 (April 25, 1993)
	AO	
	AP	

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.